Literature DB >> 11395510

Mechanisms of differential activation of target gene promoters by p53 hinge domain mutants with impaired apoptotic function.

X T Kong1, H Gao, E J Stanbridge.   

Abstract

Suppression of tumor cell growth by p53 results from the activation of both apoptosis and cell cycle arrest functions that have been shown to be separable activities of p53. We report here that some mutants in the p53 hinge domain, a short linker between the DNA binding and tetramerization domains, differentially activated the promoters of p53 target genes and possessed an impaired apoptotic function. Our results indicate that the hinge domain may play an important role in differentially regulating p53 cell cycle arrest and apoptotic functions. However, the mechanisms by which p53 hinge domain mutants differentially activate its target genes, e.g. p21(WAF1/CIP1) and Bax, remain unknown. To investigate the possible mechanisms, recombinant p21(WAF1/CIP1) and Bax promoters were constructed, resulting in rearrangement of the existing p53 binding sites within a given promoter or actually swapping p53 binding sites between the two promoters. Our results suggest that multiple mechanisms of differential transactivation occur, depending on the molecular nature of the relevant hinge domain mutant, such as the possibility that dual separate DNA binding sites in the p21(WAF1/CIP1) promoter are responsible for the selective transactivation activity of p53 hinge domain mutant del300-327, which has a large deletion in the hinge domain. Lack of ideal p53 binding sites in the Bax promoter results in less potent activation than that seen with the p21(WAF1/CIP1) promoter when it is transactivated by hinge domain point mutant mutR306P or short deletion mutant del300-308 proteins. How the single mutation or the short deletion affect the conformation of p53 and consequently the transactivation of the Bax promoter will require further investigation of the relevant p53 protein: DNA-binding domain by NMR and x-ray crystallographic techniques.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11395510     DOI: 10.1074/jbc.M103681200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  6 in total

1.  Distinct promoter elements mediate the co-operative effect of Brn-3a and p53 on the p21 promoter and their antagonism on the Bax promoter.

Authors:  C Perez-Sanchez; V S Budhram-Mahadeo; D S Latchman
Journal:  Nucleic Acids Res       Date:  2002-11-15       Impact factor: 16.971

Review 2.  Therapeutics Targeting p53-MDM2 Interaction to Induce Cancer Cell Death.

Authors:  Nayeong Koo; Arun K Sharma; Satya Narayan
Journal:  Int J Mol Sci       Date:  2022-04-30       Impact factor: 6.208

3.  Lysines in the tetramerization domain of p53 selectively modulate G1 arrest.

Authors:  Rachel Beckerman; Kathryn Yoh; Melissa Mattia-Sansobrino; Andrew Zupnick; Oleg Laptenko; Orit Karni-Schmidt; Jinwoo Ahn; In-Ja Byeon; Susan Keezer; Carol Prives
Journal:  Cell Cycle       Date:  2016-05-21       Impact factor: 4.534

4.  Wild-type and mutant p53 differentially regulate NADPH oxidase 4 in TGF-β-mediated migration of human lung and breast epithelial cells.

Authors:  H E Boudreau; B W Casterline; D J Burke; T L Leto
Journal:  Br J Cancer       Date:  2014-04-08       Impact factor: 7.640

5.  The physical interaction of p53 and plakoglobin is necessary for their synergistic inhibition of migration and invasion.

Authors:  Mahsa Alaee; Amarjot Padda; Vahedah Mehrabani; Lucas Churchill; Manijeh Pasdar
Journal:  Oncotarget       Date:  2016-05-03

Review 6.  The Emerging Landscape of p53 Isoforms in Physiology, Cancer and Degenerative Diseases.

Authors:  Thineskrishna Anbarasan; Jean-Christophe Bourdon
Journal:  Int J Mol Sci       Date:  2019-12-11       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.